JL
Jillepalli Lakshminarayana Sarma
About Jillepalli Lakshminarayana Sarma
Data last updated:
Jillepalli Lakshminarayana Sarma is a Director at Marval Biopharm Private Limited (since 2020) and Director at Pvr Med India Private Limited (since 2022). The companies operate in Pharma and Healthcare. The largest current company by reported revenue is Marval Biopharm Private Limited at ₹5.9 Lakh (FY 2022).
Current companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
 Marval Biopharm Private Limited U51909TN2020PTC138102 | Director | 21 Sep 2020 | 2020 | ₹5.9 Lakh (FY 2022) | Active |
| Pvr Med India Private Limited U33100TN2022FTC152921 | Director | 10 Jun 2022 | 2022 | Active |
Board colleagues of Jillepalli Lakshminarayana Sarma
| Name | DIN | Company | Designation |
|---|---|---|---|
| Kallada Mallissery Dilipkumar | 08888002 | Marval Biopharm Private Limited | Director |
| Daniel Vezoja | 09633484 | Pvr Med India Private Limited | Director |
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Jillepalli Lakshminarayana Sarma
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Jillepalli Lakshminarayana Sarma
Jillepalli Lakshminarayana Sarma currently holds 2 directorships: Marval Biopharm Private Limited (Director, since 21 Sep 2020, revenue ₹5.9 Lakh (FY 2022)); Pvr Med India Private Limited (Director, since 10 Jun 2022).
Jillepalli Lakshminarayana Sarma was first appointed on 21 Sep 2020 as Director at Marval Biopharm Private Limited. The most recent appointment on record is 10 Jun 2022 at Pvr Med India Private Limited.
The current boards of Jillepalli Lakshminarayana Sarma's companies include Kallada Mallissery Dilipkumar (Marval Biopharm Private Limited), Daniel Vezoja (Pvr Med India Private Limited).